Supply Chain Intelligence

Atossa Therapeutics, Inc. Supply Chain

ATOS supply chain intelligence for Atossa Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

ATOS ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
5Customers
2Debt Items
20Related Chains

Atossa Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
PRIMARY-COMMERCIAL-SUPPLIER PRIMARY-COMMERCIAL-SUPPLIER 92% In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the (Z)-endoxifen drug substance.
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIF PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-31-Z-ENDOXIF 92% In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the 31 (Z)-endoxifen drug substance.
PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-Z-ENDOXIFEN- PRIMARY-COMMERCIAL-SUPPLIER-FOR-THE-Z-ENDOXIFEN- 92% In particular, our current business structure contemplates, at least in the foreseeable future, use of a primary commercial supplier for the (Z)-endoxifen drug substance.
RODMAN-RENSHAW-LLC RODMAN-RENSHAW-LLC 92% Rodman & Renshaw LLC (the “Placement Agent”) acted as the exclusive placement agent for the Company in connection with the Offering.
INTAS-PHARMACEUTICALS-LTD INTAS-PHARMACEUTICALS-LTD 90% the Company entered into a Settlement Agreement with Intas Pharmaceuticals Ltd.
JINA-PHARMACEUTICALS-INC JINA-PHARMACEUTICALS-INC 90% the Company entered into a Settlement Agreement with Jina Pharmaceuticals, Inc.
THIRD-PARTY-INFORMATION-TECHNOLOGY-VENDOR THIRD-PARTY-INFORMATION-TECHNOLOGY-VENDOR 90% We also rely on a third-party information technology vendor to oversee our information technology systems, including our mechanisms, controls, technologies, systems, and other processes designed to h…

Atossa Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
SNYNF Sanofi 72% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our …
ATHENA-DIAGNOSTICS-INC ATHENA-DIAGNOSTICS-INC 62% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
AUSTRALIA-ATOSSA-GENETICS-AUS-PTY-LTD AUSTRALIA-ATOSSA-GENETICS-AUS-PTY-LTD 62% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…
MYRIAD-THERAPEUTICS-INC MYRIAD-THERAPEUTICS-INC 62% pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses. Our operations are based primarily in Seattle, Washington. These operations could be su…

Atossa Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ATOS-DEBT-7952 Warrants outstanding: 4318475 90% xbrl warrant detail from xbrl 2026-03-31.
ATOS-DEBT-7953 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Atossa Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Atossa Therapeutics, Inc..

Atossa Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
ATOS-OWNER-BARCLAYS-PLC BARCLAYS PLC 90% 13F overlay lists BARCLAYS PLC as top holder; 3 tracked holders.

Atossa Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CALC CalciMedica, Inc. 100.00 2
GRDX GridAI Technologies Corp. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
TECX Tectonic Therapeutic, Inc. 100.00 2
View ATOS supply chain intel →

Explore the full interactive supply chain map for Atossa Therapeutics, Inc..

Open ATOS supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map